General
Preferred name
Darolutamide
Synonyms
ODM-201 ()
BAY-1841788 ()
Darolutamide (ODM-201) ()
DAROLUTAMIDEBAY-1841788BAY1841788CS-5174 ()
BAY 1841788 ()
Darolutamida ()
BAY1841788 ()
Nubeqa ()
P&D ID
PD021518
CAS
1297538-32-9
Tags
available
drug
Drug indication
prostate carcinoma
Prostate cancer
Drug Status
approved
investigational
Max Phase
4.0
First approval
2019
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Darolutamide (ODM-201;BAY-1841788) is a potent androgen receptor (AR) antagonist with an IC50 of 26 nM in in vitro assay.
PRICE
143
DESCRIPTION
Darolutamide is a nonsteroidal, potent and selective antagonist of the androgen receptor (antiandrogen) . It is able to overcome resistance to current nonsteroidal androgen receptor-targeted therapies ( and ). Darolutamide was developed by Orion and Bayer HealthCare.
(GtoPdb)
DESCRIPTION
Darolutamide is a nonsteroidal androgen receptor antagonist. It is used for castration-resistant, non-metastatic prostate cancer.
(Enamine Bioactive Compounds)
DESCRIPTION
Darolutamide (BAY-1841788) is an androgen receptor (AR) antagonist that blocks AR nuclear translocation (Ki: 11 nM).
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
15
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
24
Molecular Weight
398.13
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
3
cLogP
2.67
TPSA
119.62
Fraction CSP3
0.26
Chiral centers
2.0
Largest ring
6.0
QED
0.59
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Androgen Receptor
Pathway
Vitamin D Related/Nuclear Receptor
Endocrinology/Hormones
Source data
